Cox-2 as a target for cancer chemotherapy

Pharmacological Reports

Volumn 62, Issue 2, 2010, Pages 233-244

  Ghosh, Nilanjan ^a   Chaki, Rituparna ^a   Mandal, Vivekananda ^b   Mandal, Subhash C ^b  

^a B C Roy College of Pharmacy and Allied Health Sciences   (India)

^b JADAVPUR UNIVERSITY   (India)

Author keywords

Angiogenesis; Apoptosis; Cancer; Cyclooxygenase; Metastasis

Indexed keywords

2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; 4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; ACETYLSALICYLIC ACID; CARBOPLATIN; CARCINOGEN; CARMUSTINE; CELECOXIB; CISPLATIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MELPHALAN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; TRASTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN SERINE THREONINE KINASE; PYRAZOLE DERIVATIVE; PYRUVATE DEHYDROGENASE (ACETYL-TRANSFERRING) KINASE; SULFONAMIDE;

ABSENCE OF SIDE EFFECTS; ADENOMATOUS POLYP; ANGIOGENESIS; APOPTOSIS; ARTHRITIS; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER RADIOTHERAPY; CARCINOGENESIS; CATALYSIS; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNE RESPONSE; INFLAMMATORY DISEASE; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG RESECTION; METASTASIS; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRECANCER; PROTEIN EXPRESSION; SARCOMA; SKIN CANCER; SOLID TUMOR; STOMACH ULCER; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHYSIOLOGY; TUMOR INVASION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; CLINICAL TRIALS AS TOPIC; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SULFONAMIDES;

EID: 77953319891     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70262-0     Document Type: Review

References (72)

1. Altorki NK, Keresztes RS, Port JL, Libby DM, Korst RJ, Flieder DB, Ferrara CA et al.: Celecoxib (Celebrex), a selective COX-2 inhibitor, enhances the response to preoperative paclitaxel/carboplatin in early stage nonsmall cell lung cancer. Proc Am Soc Clin Oncol, 2002, 21, 101.
2. Altorki NK, Keresztes RS, Port JL, Libby DM, Korst RJ, Flieder DB, Ferrara CA et al.: Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage nonsmall-cell lung cancer. J Clin Oncol, 2003, 21, 2645-2650.
3. Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P, Ogier-Denis E: Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem, 2002, 277, 27613-27621.
4. Badawi AF, Badr MZ: Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma. Int J Oncol, 2002, 20, 1109-1122.
5. Balch CM, Dougherty PA, Cloud GA, Tilden AB: Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients. Surgery, 1984, 95, 71-77.
6. Bamba H, Ota S, Kato A, Adachi A, Itoyama S, Matsuzaki F: High expression of cyclooxygenase-2 in macrophages of human colonic adenoma. Int J Cancer, 1999, 83, 470-475.
7. Buchanan FG, Wang D, Bargiacchi F, DuBois RN: Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem, 2003, 278, 35451-35457.
8. Chandrasekharan NV, Dai H, Roos KL: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs cloning, structure and expression. Proc Natl Acad Sci USA, 2002, 99, 13926-13931.
9. Chen CC, Sun YT, Chen JJ, Chang YJ: Tumor necrosis factor-α induced cyclooxygenase-2 expression via sequential activation of ceramide-dependent mitogenactivated protein kinases, and IB kinase 1/2 in human alveolar epithelial cells. Mol Pharmacol, 2001, 59, 493-500.
10. Chow LW, Wong JL, Toi ML: Celecoxib anti-aromatase neoadjuvant trial for locally advanced breast cancer: preliminary report. J Steroid Biochem Mol Biol, 2003, 86, 443-447.
11. Cok SJ, Morrison AR: The 3'untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency. J Biol Chem, 1997, 272, 21455-21460.
12. Csiki I, Dang T, Gonzalez A, Gautam S, Sandler A, Campbell N, Garcia B et al.: Cyclooxygenase-2 inhibition + docetaxel in recurrent non-small cell lung cancer: preliminary results of a phase II trial (THO-0054). Proc Am Soc Clin Oncol, 2002, 21, 1187.
13. 2 is a mediator of cyclooxygenase-2- dependent endothelial cell migration and angiogenesis. Cancer Res, 1999, 59, 4574-4577.
14. Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB, Subbaramaiah K: Cyclooxygenase-2: a pharmacological target for the prevention of cancer. Lancet Oncol, 2001, 2, 544-551.
15. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN: Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol, 2005, 23, 254-266.
16. Dannenberg AJ, Zakim D: Chemoprevention of colorectal cancer through inhibition of cyclooxygenase-2. Semin Oncol, 1999, 26, 499-504.
17. Dempke W, Rie C, Grothey A, Schmoll HJ: Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol, 2001, 127, 411-417.
18. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 1994, 107, 1183-1188.
19. Ek M, Engblom D, Saha S, Blomqvist A, Jakobsson PJ, Ericsson-Dahlstrand A: Inflammatory response pathways across the blood-brain barrier. Nature, 2001, 410, 430-431.
20. Eling TE, Thompson DC, Foureman GL, Curtis JF, Hughes MF: Prostaglandin H synthase and xenobiotic oxidation. Annu Rev Pharmacol Toxicol, 1990, 30, 1-45.
21. Fernandez PM, Manyak MJ, Patierno SR: Effect of the cyclooxygenase-2 selective inhibitor NS398 on the secretion of matrix metalloproteinases (MMP-2 and MMP-9) and tissue inhibitors of metalloproteinase (TIMP-1 and TIMP-2) from human prostate tumor cells. Proc Am Assoc Cancer Res, 2000, 41, 131-132.
22. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med, 1971, 285, 1182-1186.
23. Hla T, Neilson K: Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA, 1992, 89, 7348-7384.
24. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS: The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem, 2000, 275, 11397-11403.
25. 2+ATPases: a plausible link with its antitumour effect and cardiovascular risks. Biochem J, 2002, 66, 831-837.
26. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM: Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem, 1993, 268, 9049-9054.
27. Kakiuchi Y, Tsuji S, Tsujii M: Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens in colon cancer cells and enhanced liver metastasis. Cancer Res, 2002, 62, 1567-1572.
28. Kambayashi T, Alexander HR, Fong M, Strassmann G: Potential involvement of IL-10 in suppressing tumorassociated macrophages. Colon-26-derived prostaglandin E2 inhibits TNF-alpha release via a mechanism involving IL-10. J Immunol, 1995, 154, 3383-3390.
29. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S: Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res, 1995, 55, 2556-2559.
30. Kerbel R, Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer, 2002, 2, 727-739.
31. Kishi K, Petersen S, Petersen C, Hunter N, Mason K, Masferrer JL, Tofilon PJ et al.: Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res, 2000, 60, 1326-1331.
32. Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, Fowble JW et al.: 3-Phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res, 2004, 64, 1444-1451.
33. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C et al.: Over-expression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem, 2001, 276, 18563-18569.
34. Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX, DuBois RN: Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology, 2001, 120, 1713-1719.
35. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA et al.: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res, 2000, 60, 1306-1311.
36. Meade EA, Mcintyre TM, Zimmerman GA, Prescott SM: Peroxisome proliferators enhance cyclo-oxygenase-2 expression in epithelial cells. J Biol Chem, 1999, 274, 8328-8334.
37. Muller-Decker K, Neufang G, Berger I, Neumann M, Marks F, Furstenberger G: Transgenic cyclooxygenase-2 over-expression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci USA, 2002, 99, 12483-12488.
38. Niiro H, Otsuka T, Izuhara K: Regulation by interleukin-10 and interleukin-4 of cyclooxygenase-2 expression in human neutrophils. Blood, 1997, 89, 1621-1628.
39. O'Banion MK, Sadowski HB, Winn V, Young DA: A serum and glucocorticoid regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem, 1991, 266, 23261-23267.
40. Δ716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell, 1996, 87, 803-809.
41. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS: Prostaglandin E2 transactivates EGF receptor a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med, 2002, 8, 289-293.
42. Peppelenbosch MP, Tertoolen LG, Hage WJ, de Laat SW: Epidermal growth factor-induced actin remodeling is regulated by 5-lipoxygenase and cyclooxygenase products. Cell, 1993, 74, 565-575.
43. Pollard JW: Tumor-educated macrophages promote tumor progression and metastasis. Nat Rev Cancer, 2004, 4, 71-78.
44. Pyo H, Choy H, Amorino GP, Kim JS, Cao Q, Hercules SK, DuBois RN: A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res, 2001, 7, 2998-3005.
45. Pyrko P, Kardosh A, Liu YT, Soriano N, Xiong W, Chow RH, Uddin J et al.: Calcium-activated ER stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib (DMC), a non-coxib analog of celecoxib. Mol Cancer Ther, 2007, 6, 1262-1275.
46. Rao CV, Kawamori T, Hamid R, Reddy BS: Chemoprevention of colonic aberrant crypt foci by an inducible nitic oxyde synthase-selective inhibitor. Carcinogenesis, 1999, 20, 641-644.
47. Reddy BS: Novel approaches to the prevention of colon cancer by nutritional manipulation and chemoprevention. Cancer Epidemiol Biomarkers Prev, 2000, 9, 239-247.
48. Rodrigues S, Bruyneel E, Rodrigue CM, Shahin E, Gespach C: Cyclooxygenase 2 and carcinogenesis. Bull Cancer, 2004, 91, S61-S76.
49. γ enhance colon polyp formation. Nat Med, 1998, 4, 1058-1061.
50. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S et al.: Expression of cyclooxygenase-1 and 2 in human colorectal cancer. Cancer Res, 1995, 55, 3785-3789.
51. Shao J, Lee SB, Guo H, Evers BM, Sheng H: Prostaglandin E stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res, 2003, 63, 5218-5223.
52. Sheng H, Shao J, Dixon DA, Williams CS, Prescott SM, DuBois RN, Beauchamp RD: Transforming growth factorβ1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J Biol Chem, 2000, 275, 6628-6635.
53. Sheng H, Shao J, Dubois RN: K-Ras-mediated increase in cyclooxygenase 2 mRNAstability involves activation of the protein kinase B. Cancer Res, 2001, 61, 2670-2675.
54. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN: Modulation of apoptosis and Bcl-2 expression by prostaglandin E in human colon cancer cells. Cancer Res, 1998, 58, 362-366.
55. Sheng H, Williams CS, Shao J, Liang P, DuBois RN, Beauchamp RD: Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway. J Biol Chem, 1998, 273, 22120-22127.
56. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, Isakson PC et al.: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA, 1999, 282, 1921-1928.
57. Smith WL, DeWitt DL, Garavito RM: Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem, 2000, 69, 145-182.
58. Smith WL, Langenbach R: Why there are two cyclooxygenase isozymes. J Clin Invest, 2001, 107, 1491-1495.
59. Δ716 knockout mice. Nat Med, 2001, 7, 1048-1051.
60. Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J, Zhu L et al.: Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol, 2000, 164, 361-370.
61. Takahashi T, Kozaki K, Yatabe Y, Achiwa H, Hida T: Increased expression of Cox2 in the development of human lung cancers. J Environ Pathol Toxicol Oncol, 2002, 21, 177-181.
62. Teicher BA, Korbut TT, Menon K, Holden SA, Ara G: Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies. Cancer Chemother Pharmacol, 1994, 33, 515-522.
63. Tomozawa S, Nagawa H, Tsuno N, Hatano K, Osada T, Kitayama J, Sunami E et al.: Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor JTE-522. Br J Cancer, 1999, 81, 1274-1279.
64. Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D: Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer, 2002, 87, 21-27.
65. Tsujii M, DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells over-expressing prostaglandin endoperoxide synthase 2. Cell, 1995, 83, 493-501.
66. Tsujii M, Kawano S, DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA, 1997, 94, 3336-3340.
67. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell, 1998, 93, 705-716.
68. Uefuji K, Ichikura T, Mochizuki H: Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res, 2000, 6, 135-138.
69. Wiese FW, Thompson PA, Kadlubar FF: Carcinogen substrate specificity of human COX-1 and COX-2. Carcinogenesis, 2001, 22, 5-10.
70. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN: Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest, 2000, 105, 1589-1594.
71. Zhang F, Subbaramaiah K, Altorki N, Dannenberg AJ: Dihydroxy bile acids activate the transcription of cyclooxygenase-2. J Biol Chem, 1998, 273, 2424-2428.
72. Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, Shiau CW, Shaw YJ et al.: From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3 phosphoinositidedependent protein kinase-1 inhibitors. Cancer Res, 2004, 64, 4309-4318.